QDEL - Quidel Corporation
| Previous Close | 61.62 |
| Open | 61.59 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 60.37 - 62.09 |
| 52 Week Range | 44.27 - 77.63 |
| Volume | 119,310 |
| Avg. Volume | 186,548 |
| Market Cap | 2.421B |
| Beta (3Y Monthly) | 1.62 |
| PE Ratio (TTM) | 37.91 |
| EPS (TTM) | 1.60 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 68.83 |
- Simply Wall St.
Investors Who Bought Quidel (NASDAQ:QDEL) Shares Three Years Ago Are Now Up 190%
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...
- Thomson Reuters StreetEvents
Edited Transcript of QDEL earnings conference call or presentation 6-Nov-18 10:00pm GMT
Q3 2018 Quidel Corp Earnings Call
Motley FoolQuidel (QDEL) Q2 2019 Earnings Call Transcript
QDEL earnings call for the period ending June 30, 2019.
- Zacks
Quidel (QDEL) Q2 Earnings Meet Estimates
Quidel (QDEL) delivered earnings and revenue surprises of 0.00% and 0.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Quidel Reports Second Quarter 2019 Financial Results
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2019.
- Investor's Business Daily
Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish Sign
Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.
- Simply Wall St.
Is Quidel Corporation's (NASDAQ:QDEL) CEO Being Overpaid?
In 2009 Doug Bryant was appointed CEO of Quidel Corporation (NASDAQ:QDEL). This report will, first, examine the CEO...
- Zacks
Quidel (QDEL) Reports Next Week: Wall Street Expects Earnings Growth
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GuruFocus.com
Quidel Corp (QDEL) President & CEO Douglas C Bryant Sold $1.3 million of Shares
President & CEO of Quidel Corp (30-Year Financial, Insider Trades) Douglas C Bryant (insider trades) sold 21,789 shares of QDEL on 07/29/2019 at an average price of $57.78 a share. Continue reading...
- Business Wire
Quidel to Hold Second Quarter 2019 Financial Results Conference Call on August 8th, 2019
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report second quarter 2019 financial results after market close on Thursday, August 8, 2019.
- Simply Wall St.
Brief Commentary On Quidel Corporation's (NASDAQ:QDEL) Fundamentals
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I...
- Business Wire
Quidel Receives 510(k) Clearance for Quidel Triage® TOX Drug Screen, 94600 Toxicology Test for Use With Quidel’s Triage® MeterPro Instrumented System
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received 510(k) clearance from the Unites States Food and Drug Administration (FDA) to market the Quidel Triage® TOX Drug Screen, 94600, a fluorescence immunoassay for the qualitative determination of the presence of drug and/or metabolites in human urine of up to 9 drug assays. The test is to be used with Quidel’s Triage® MeterPro instrumented system.
- Zacks
Medical Products Industry Outlook: Growth Prospects Radiant
Medical Products Industry Outlook: Growth Prospects Radiant
- Zacks
QDEL vs. BAX: Which Stock Is the Better Value Option?
QDEL vs. BAX: Which Stock Is the Better Value Option?
- Zacks
Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
- Insider Monkey
Is Quidel Corporation (QDEL) A Good Stock To Buy?
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
- Zacks
Zacks.com featured highlights include: lululemon, Quidel, China Yuchai and Logitech
Zacks.com featured highlights include: lululemon, Quidel, China Yuchai and Logitech
- Zacks
Ecolab Unveils Innovative Tested Tool to Improve Food Safety
Ecolab's (ECL) innovative tested tool aims to improve food safety and ensure customer safety.
- Zacks
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
- Zacks
Here's Why You Should Retain HMS Holdings (HMSY) Stock
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.
- Zacks
4 Top Efficient Stocks to Boost Your Portfolio
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
- Simply Wall St.
Should You Be Adding Quidel (NASDAQ:QDEL) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- Zacks
Here's Why You Should Retain NextGen Healthcare (NXGN) Stock
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
- Zacks
Here's Why You Should Invest in DexCom (DXCM) Stock Now
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
- Business Wire
Quidel Announces Private Exchange Transactions
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.25% Convertible Senior Notes due 2020 (the “2020 Notes”). Pursuant to these exchange agreements Quidel will exchange approximately $45.372 million in aggregate principal amount of the 2020 Notes for (i) approximately 1,273,601 shares of the company’s common stock plus (ii) an additional number of newly issued shares of the company’s common stock to be determined based on the volume weighted average price of the company’s common stock over the three consecutive trading days commencing on June 5, 2019.
